Memphis to re-study marketing, sales plans after halting 33 drugs

Aspirin occupies 26.7% of the company sales

ArabFinance: The Central Auditing Organization (CAO) asked Memphis Pharmaceutical (MPCI) to restudy marketing and sales plans to its drugs in order to activate sales, according to Al Mal news website.

The request comes after the company has halted production of 33 medicines with a value of returns amounted around EGP 803,000.

According to CAO notes on Memphis’ financial results, Aspirin occupies 26.7% of the company sales at EGP 131.23 million, however, Memphis only packs it.

On the other hand, the sale of Devarol, which is produced by the company, acquire 8.9% of the Memphis’ sales at EGP 44.195 million.

The company posted a net profit before tax of EGP 2.920 million in July-August period for the fiscal year 2020/2021, a 143% rise from EGP 1.200 million achieved in the prior-year period.

Memphis Company is one of the companies of the drug holding company in Egypt. It is considered one of the oldest pharmaceutical and chemical companies in the Middle East since 1940.

Copyright © 2020 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From North Africa